Actively Recruiting
Impact of Human Papillomavirus Carriage on IVF/ICSI Results (HPV AMP)
Led by University Hospital, Brest · Updated on 2024-08-13
618
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The prevalence of the papilloma virus in the general population is 12%. This virus is known to impair male fertility but its impact on female infertility remains uncertain. This is a public health problem since there is a vaccination protocol. Demonstrating the impact of the human papillomavirus on fertility would be an argument in favor of vaccination.
CONDITIONS
Official Title
Impact of Human Papillomavirus Carriage on IVF/ICSI Results (HPV AMP)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women aged 25 to under 38 years
- Any cause of infertility
- AMH (anti-Müllerian hormone) level of 1.1 ng/ml or higher
- Undergoing first or second IVF treatment protocol
You will not qualify if you...
- Age under 25 years
- Age 38 years or older
- AMH level below 1.1 ng/ml
- Patients under legal protection
- Decline to participate in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHRU de Brest
Brest, France, 29609
Actively Recruiting
Research Team
S
Sarah BOUEE
CONTACT
A
Anne-Solenn JACAMON
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here